Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059960 | 0.82 | KDM4E (0.46) | CCR9KMT2AKDM4EALDH1A1JAK2 | |
| SCHEMBL3048687 | 0.78 | CCR9 (0.47) | CCR9KMT2AKDM4EALDH1A1JAK2 | |
| SCHEMBL3064581 | 0.76 | KDM4E (0.41) | CCR9KDM4EALDH1A1MAPT | |
| SCHEMBL3059141 | 0.76 | CCR9 (0.38) | CCR9KDM4EALDH1A1MAPT | |
| SCHEMBL3059137 | 0.76 | CCR9 (0.38) | CCR9KDM4EALDH1A1MAPT | |
| SCHEMBL7688499 | 0.71 | CCR9 (0.43) | CCR9KDM4EALDH1A1JAK2JAK1 | |
| SCHEMBL31618907 | 0.71 | KDM4E (0.38) | KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL18338266 | 0.71 | KDM4E (0.65) | KMT2AKDM4EALDH1A1MAPTTP53 | |
| SCHEMBL19301507 | 0.70 | KMT2A (0.36) | KMT2AJAK2JAK1JAK3MAPT | |
| SCHEMBL20536218 | 0.70 | RHEB (0.47) | KMT2AALDH1A1MAPTPTGS2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197438-B1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUAN (CN) | 2015-07-15 | — | — | EP | disclosed |
| US-8772312-B2 | Heterocyclic compounds as CRTH2 receptor antagonists | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMETEK, LLC | 2010-09-02 | — | — | US | disclosed |
| EP-2197438-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | Chemietek, Llc (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009049021-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, NR3C2, HRH1 | CCR9 650/4885KMT2A 3223/4885KDM4E 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.